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Current treatment strategy for chronic myeloid leukemia (CML) mainly includes inhibition of 
tyrosine kinase activity, which has dramatically improved the prognosis of the disease but 
without cure1. In addition some patients may become drug-resistant1.  Thus there is still the need 
for other therapies to avoid resistance and if possible to cure the disease1. Loss of p53 is known to 
play an important role in the disease progression of CML and causes drug resistance2. Here, I 
propose that in CML, inositol requiring enzyme – 1 alpha (IRE – 1α) may cause abnormal 
degradation of p53 mRNA resulting in inhibition of apoptosis in leukemic clonal cells, which has 
not been elucidated before. Hence, I propose that inhibition of endoribonuclease activity of IRE – 
1α with small molecule inhibitors may provide a novel strategy to enhance p53 function in CML 
leukemic clones to overcome the limitations of current treatment regimens.  
 
CML is a malignant disorder arising from a translocation occurring in a hematopoietic 
stem cell, which leads to the Bcr – Abl fusion gene3 encoding the protein p210BCR/ABL, 
a constitutively active form of Abl tyrosine kinase1. CML phenotype is very strongly 
related to the dramatic expansion of hematopoietic progenitors4 and the progression to 
acute leukemia in a few years. Concerning to the current therapeutic outcomes, 
majority of the patients require life – long therapeutic intervention, which permits a 
clinical, hematological and molecular remission avoiding the progression to acute 
leukemia. However long term treatment with tyrosine kinase inhibitors may induce 
non – hematological toxicities. In addition, in around 5% of patients, progression may 
occur under tyrosine kinase inhibitor treatment. In these cases, allogeneic bone 
marrow transplantation is the only curative alternative, but requires an HLA matching 
donors and is associated with an important morbidity. 
 
In CML, loss of p53 function is known to induce drug resistance and aggressive 
progression to blast crisis2. But it is not known that even though when the p53 allele is 
unmutated and exists with intact gene regulatory elements how loss of p53 mRNA 
expression occurs during disease progression of CML2, 5, 6, 7. It has been suggested 
that downregulated p53 protein expression in CML could be due to either 
destabilization of its mRNA or epigenetic modulation5. Further, it has been 
demonstrated that down – regulated p53 protein expression in CML is not due to 
defective epigenetic modulation or defective transcriptional factor function 
responsible for activation of p53 gene expression7, which suggests that down – 
regulation of p53 function in CML is possible through destabilization of p53 mRNA 
also.  
 
Previously it has been demonstrated that, unfolded protein response (UPR) pathway is 
a downstream target of Bcr – Abl and that UPR confers anti – apoptotic response8 
which indicates that UPR may be aberrantly activated in CML leukemic clonal cells. 
IRE – 1α is an evolutionarily conserved member of UPR pathway and is found to be 
over – expressed in Bcr – Abl expressing cells8. From the known findings, IRE – 1α  
has mainly two functions, endoribonuclease and serine/threonine kinase activities. 
IRE – 1α  can be activated by either ER stress or over – expression9. IRE – 1α is 
capable of degrading the target mRNAs by a mechanism called Regulated Ire – 1 
Dependent Decay (RIDD)9. IRE – 1α induces mRNA degradation by recognising the 
CUGCAG consensus element accompanied by stem – loop structure in target 
mRNAs10.  
 
In the analysis, I found that in the p53 mRNA, IRE – 1α recognition consensus 
element CUGCAG is accompanied by stem – loop structure. This stem – loop 
structure is formed from the residue 2218 to 2231 and the recognition consensus 
element exists from residue 2224 to 2229 in the p53 mRNA. The difference in Gibbs 
free energy before and after formation of this stem – loop structure is -3.5 units of 
Gibbs free energy for 14 nucleotide chain calculated by Mfold web server14 indicating 
that the formation of this stem – loop structure in the p53 mRNA is spontaneous thus 
its formation is highly favourable thermodynamically. Hence, the demonstration that 
inhibition of IRE – 1α diminishes anti – apoptotic response in CML leukemic clonal 
cells8 could be mainly due to increased p53 protein expression. Therefore, I propose 
that inhibition of endoribonuclease activity of IRE – 1α with small molecule 
inhibitors to enhance p53 function in CML leukemic clones as a novel strategy to 
overcome limitations of current treatment regimens.  
 
Results and model for the mechanism: 
 
Figure 1 : Nucleotide alignment of p53 mRNA and IRE – 1α recognition consensus element 
(CUGCAG) using EMBOSS Needle11, 12, 13 
 
 
 
                                       
Figure 2 : IRE – 1α recognition consensus element CUGCAG accompanied by stem – loop 
structure in the p53 mRNA determined by using Mfold Web Server14 
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Figure 3 : Schematic diagram of the model for loss of p53 protein expression in CML 
 
 
 
 
References : 
 
1. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to  
    patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol    
    Educ Program (2011). 
 
2. Wendel HG, de Stanchina E, Cepero E et al. Loss of p53 impedes the antileukemic response to    
    BCR-ABL inhibition. PNAS (2006), vol 3 7444–7449. 
 
3. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia  
    identified by quinacrine fluorescence and Giemsa staining. Nature (1973); 243: 290–3 
 
4. Spiers AS. The clinical features of chronic granulocytic leukaemia. Clin. Haematol (1977) 6: 77-95.  
 
5. Durland-Busbice S and Reisman D. Lack of p53 expression in human myeloid leukemias is not due  
    to mutations in transcriptional regulatory regions of the gene. Leukemia (2002), vol 16 2165-2167. 
6. Ahuja H, Bar-Eli M, Advani SH et al. Alterations in the p53 gene and the clonal evolution of the       
blast crisis of chronic myelocytic leukemia. PNAS (1989) Sep;86(17):6783-7. 
 
	  
Endoplasmic Reticulum 
Bcr – Abl  
Overexpression	   
of	  IRE	  –	  1α 
IRE	  –	  1α	  
dimer 
Abnormal mRNA degradation  
of WT p53 
Cytosol 
	   Stress Cytosol 
	   	   	   	   	   	  	   	  
7. Lübbert M, Miller CW, Crawford L et al. p53 in chronic myelogenous leukemia. Study of   
mechanisms of differential expression. Journal of Experimental Medicine (1988), Mar 1;167(3):873-
86. 
 
8. Tanimura A, Yujiri T, Tanaka Y et al. The anti-apoptotic role of the unfolded protein response in  
    Bcr-Abl-positive leukemia cells. Leukemia Research (2009) ;33:924–8.  
 
9.Yoshida H, Matsui T, Yamamoto A et al. XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in  
   Response to ER Stress to Produce a Highly Active Transcription Factor. Cell (2001), vol 107 881– 
   891. 
 
10. Oikawa D, Tokuda M, Hosoda A et al. Identification of a consensus element recognized and  
    cleaved by IRE1α. Nucleic Acids Research (2010), Vol. 38, No. 18 6265–6273. 
 
11. EMBOSS: the European Molecular Biology Open Software Suite. Trends in genetics (2000) : TIG  
     16 (6) :276-7 
 
12. The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic acids research  
     (2015) 43 (W1) :W580-4 
 
13. Analysis Tool Web Services from the EMBL-EBI. Nucleic acids research (2013) 41 (Web Server  
      issue) :W597-600 
 
14. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids  
     Research (2003), 3406–3415. 
 
 
Acknowledgement: 
 
I am thankful to Dr. Sweta Srivastava (St. John’s Medical Hospital, India) for the 
critical discussion. I was supported by fellowships from L’Institut national de la santé 
et de la recherche médicale (INSERM), France, GLUE Grant Initiative, Department 
of Biotechnology, Governement of India and travel scholarship from the Service for 
Science and Technology at the French Embassy (SST), New Delhi, India. 
 
 
 	  
 
 
 	  
 
